HIV-1 resistance mutations and plasma RNA during zidovudine plus zalcitabine combination therapy

被引：0
|
作者：
Sylvester, A
Caliendo, A
An, D
Savara, A
Byington, R
Strick, D
Lillaney, R
Sutton, L
Sepkowitz, K
Fischl, M
Simon, G
Lalezari, J
Mitsuyasu, R
DAquila, R
机构：
[1] NEW YORK HOSP,NEW YORK,NY 10021
[2] UNIV MIAMI,MIAMI,FL 33152
[3] WASHINGTON UNIV,ST LOUIS,MO
[4] UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143
[5] UNIV CALIF LOS ANGELES,LOS ANGELES,CA
[6] MASSACHUSETTS GEN HOSP,BOSTON,MA 02114
[7] HARVARD UNIV,SCH MED,BOSTON,MA
来源：
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1995年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [31] Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy
    Brown, AJL
    Cleland, A
    AIDS, 1996, 10 (10) : 1067 - 1073
  • [32] Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine
    Opravil, M
    Hill, AM
    DeMasi, R
    Dawson, D
    ANTIVIRAL THERAPY, 1998, 3 (03) : 169 - 176
  • [33] The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
    Kempf, DJ
    Rode, RA
    Xu, Y
    Sun, E
    Heath-Chiozzi, ME
    Valdes, J
    Japour, AJ
    Danner, S
    Boucher, C
    Molla, A
    Leonard, JM
    AIDS, 1998, 12 (05) : F9 - F14
  • [34] HIV-1 plasma RNA and risk of HIV-1 transmission
    Lingappa, J. R.
    Hughes, J. P.
    Donnel, D.
    Baeten, J. M.
    Mullins, J. I.
    Campbell, M. S.
    Gray, G. E.
    Essex, M.
    Farquhar, C.
    Rees, H.
    Wald, A.
    Corey, L.
    Celum, C.
    RETROVIROLOGY, 2009, 6
  • [35] Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
    Staszewski, S
    Morales-Ramirez, J
    Tashima, KT
    Rachlis, A
    Skiest, D
    Stanford, J
    Stryker, R
    Johnson, P
    Labriola, DF
    Farina, D
    Manion, DJ
    Ruiz, NM
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25): : 1865 - 1873
  • [36] Failure to select HIV-1 with dual resistance to zidovudine and foscarnet
    Tachedjian, G
    Hooker, DJ
    Gurusinghe, AD
    Deacon, NJ
    Birch, C
    Mills, J
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 17 - 17
  • [37] MOLECULAR ASPECT OF HIV-1 RESISTANCE TO ZIDOVUDINE AND ITS REVERSAL
    CAMSONNE, R
    BIGOT, MC
    BUSTANY, P
    POTTIER, D
    VERGNAUD, M
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (05) : 137 - 138
  • [38] CLINICAL-SIGNIFICANCE OF HIV-1 INVITRO RESISTANCE TO ZIDOVUDINE
    TUDORWILLIAMS, G
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (06): : 674 - 674
  • [39] Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study
    Prosperi, Mattia C. F.
    Mackie, Nicola
    Di Giambenedetto, Simona
    Zazzi, Maurizio
    Camacho, Ricardo
    Fanti, Iuri
    Torti, Carlo
    Soennerborg, Anders
    Kaiser, Rolf
    Codoner, Francisco M.
    Van Laethem, Kristel
    Bansi, Loveleen
    van de Vijver, David A. M. C.
    Geretti, Anna Maria
    De Luca, Andrea
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (08) : 1886 - 1896
  • [40] A fossil record of zidovudine resistance in transmitted isolates of HIV-1
    Kuritzkes, DR
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) : 13485 - 13487
12345